Heparan sulfate proteoglycans undergo differential expression alterations in left sided colorectal cancer, depending on their metastatic character by Crespo Susperregui, Ainara et al.
RESEARCH ARTICLE Open Access
Heparan sulfate proteoglycans undergo
differential expression alterations in left
sided colorectal cancer, depending on their
metastatic character
Ainara Crespo1, Olivia García-Suárez2, Iván Fernández-Vega3,4, María Pilar Solis-Hernandez5, Beatriz García6,
Sonia Castañón1 and Luis M. Quirós6*
Abstract
Background: Heparan sulfate proteoglycans (HSPGs) are complex molecules which play a role in the invasion and
growth and metastatic properties of cancerous cells. In this work we analyze changes in the patterns of expression
of HSPGs in left sided colorectal cancer (LSCRC), both metastatic and non-metastatic, and the results are also
compared with those previously obtained for right sided tumors (RSCRCs).
Methods: Eighteen LSCRCs were studied using qPCR to analyze the expression of both the proteoglycan core
proteins and the enzymes involved in heparan sulfate chain biosynthesis. Certain HSPGs also carry chondroitin
sulfate chains and so we also studied the genes involved in its biosynthesis. The expression of certain genes that
showed significant expression differences were also analysed using immunohistochemical techniques.
Results: Changes in proteoglycan core proteins were dependent on their location, and the main differences
between metastatic and non-metastatic tumors affected cell-surface glypicans, while other molecules were quite
similar. Glypicans were also responsible for the main differences between RS- and LS- malignances. Regarding the
biosynthesis of heparan sulfate chains, differential alterations in transcription depending on the presence or not of
metastasis affected genes involved in the modification of uronic acid (epimerization and 2-O sulfation), and some
isoforms responsible for sulfation of glucosamine (NDST1, HS6ST1). Moreover, in RSCRCs differences were
preferentially found in the expression of genes involved in C6 and C3 sulfation of glucosamine, but not in NDSTs or
SULFs. Finally, synthesis of chondroitin sulfate showed some alterations, which affected various steps, including
polimerization and the modification of chains, but the main variations dependent on the presence of metastases
were epimerization and 6C sulfation; however, when compared with RSCRCs, the essential divergences affected
polymerization of the chains and the 6C sulfation of the galactosamine residue.
Conclusions: We evidenced alterations in the expression of HSPGs, including the expression of cell surface core
proteins, many glycosiltransferases and some enzymes that modify the GAG chains in LSCRCs, but this was
dependent on the metastatic nature of the tumor. Some of these alterations are shared with RSCRCs, while others,
focused on specific gene groups, are dependent on tumor localization.
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Background
Colorectal cancer (CRC) is a heterogeneous disease and,
despite their similar histological aspect, there are substan-
tial differences between left- and right sided CRCs
(LSCRCs and RSCRCs), including their etiology, response
to screening tests, the stage at which they are diagnosed,
and their effect on mortality [1]. At the molecular level,
differences in the expression of different biomarkers have
been described between LS- and RSCRCs.
Interestingly, several of these markers are related to
heparan sulfate proteoglycans (HSPGs) including: p53,
related to the regulation of genes as SULF2 and hepara-
nase [2, 3]; MUC1, involved in cell-cell dissociation and
invasiveness, in cooperation with HSPGs [4]; the Wnt/
β-catenin pathway, regulated by glypican-3 and -4 [5, 6];
cytokines like VEGF, EGF and TGF-beta and other
markers, which bind to heparan sulfate (HS) chains,
which regulate their activity [7–9].
HSPGs comprise a specific small group of glycoconjugates
composed of various core proteins post-translationally modi-
fied with HS glycosaminoglycan (GAG) chains. HS is a com-
plex linear anionic polysaccharide whose synthesis occurs
mainly in the Golgi apparatus. It is initiated by the formation
of a tetrasaccharide linkage on the protein core after which
the HS chain is elongated by the addition of alternating
D-glucuronic acid (GlcA) and N-acetyl-D-glucosamine
(GlcNAc) residues. Subsequently, a series of different
enzymatic reactions act in an orderly manner on specific
regions of the molecule, including N-sulfation, epimerization
and various O-sulfations. This gives rise to highly sulfated
regions (NS domains), which alternate with nonsulfated (NA
domains) and mixed (NA/NS) domains [10, 11].
Since function ultimately relies on the fine structure of the
chains, cells exercise accurate control over HSPG compos-
ition and sequence, which results in these molecules varying
depending on factors like cell type and development stage, as
well as due to pathological processes. The binding sites for a
great variety of ligands, such as cytokines, chemokines,
growth factors, enzymes and extracellular matrix (ECM)
proteins [11, 12] are defined by specific sets of variably
modified disaccharides, usually within the NS domains.
These networks of complex interactions at the molecular
level mean that HSPGs participate actively in the control of
many normal physiological functions [10–13]. Because of
these interactions, HS is also involved in many pathologies,
including inflammation, amyloid diseases, infectious diseases
and cancer [14]. Given that function is dictated by the fine
structure of the chains, the detailed analysis the full set of
changes in the expression of HSPG core proteins and HS
biosynthetic enzymes in cancer pathologies is of great
interest, as is a detailed consideration of the effect of these
particular signatures on invasion and metastasis.
Up- or downregulation of genes involved in the biosyn-
thesis of HSPGs have been reported in many cancerous
cells [15]. In the case of CRCs, various alterations have
been described, for example, those relating to specific syn-
decans [16], the relative amounts and structure of glycos-
aminoglycans [17, 18] and the expression levels of certain
enzymes involved in HS saccharidic chain structure [19,
20]. However, many of the previous studies reported in
the literature analyze this pathology in a general way even
though, as indicated above, CRC is a heterogeneous dis-
ease with respect to the anatomical location of the tumor.
We recently published the results of a study focused on
RSCRCs [21] where, since the presence or absence of me-
tastases in lymph nodes is a key predictor of progression,
we subdivided the tumors into two groups according to
this important feature. We found that the number of genes
affected was higher in non-metastatic tumors, with around
40% of all genes analyzed being involved, and that most of
the genes whose expression was altered in metastatic ma-
lignances also showed altered expression in non-metastatic
tumors. Additionally, the PGs located at the cell surface
showed significant differences in expression depending on
the presence or absence of metastases, while alterations of
those located in the ECM or within the cell were very
similar in both tumor types. HS chains seemed to experi-
ence far more limited changes in metastatic CRCs than in
non-metastatic tumors, while chondroitin sulfate (CS)
chains, which are also carried by some HSPGs, were
strongly affected, albeit differently in the two tumor groups
[21]. In this current paper, we have investigated the
expression patterns of all the genes involved in HSPG
biosynthesis in LSCRCs, compared with healthy tissues
from the same patients. As in the previous study focusing
on RSCRCs, the tumors were subdivided into two groups
according to presence or absence of metastases in lymph
nodes, and the study included genes coding for HSPG core
protein and GAG chain synthesis and modification. The
aim of the work is to increase our knowledge of structural
alterations of HSPGs in LSCRCs, comparing the data to
that previously obtained for RSCRCs, in an attempt to
define biomarkers which are different in metastatic and
non-metastatic tumors which could be useful in the future
to develop new chemical biology approaches to retard
tumor progression by modulating deregulated biosynthetic
pathways.
Methods
Tissue samples
We analyzed a cohort of 36 snap frozen colon samples, ob-
tained from the Tumor Bank at the Instituto de Oncología
Asturias (IUOPA, Asturias, Spain). 18 of the samples were
from LSCRCs, while the remaining 18 were used as control
and were from the corresponding surrounding healthy
tissue from the same patients. Diagnoses were carried out
according to the World Health Organization (WHO)
criteria using hematoxylin-eosin-stained slides and the snap
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frozen tissues were stored at − 80 °C prior to isolation of
the RNA. Informed written consent of all the patients was
obtained, and the study was approved by the Ethics
Committee on Clinical Investigation of the Hospital
Universitario Central de Asturias.
Total RNA isolation and cDNA synthesis
Tissue fragments (20–30 mg) were homogenized using a
polytron PT 2100 (Kinematica Inc.; Bohemia, NY), and
RNA was isolated using the RNeasy kit (Qiagen, Hilden,
Germany), and processed as previously described [21].
cDNA synthesis was carried out using the High Capacity
cDNA Transcription Kit (Applied Biosystems, Foster City,
CA, USA). The reactions were performed and the
products cleaned and stored as previously described [21].
Quantitative real-time polymerase chain reactions (qRT-PCR)
qRT-PCR reactions, and analysis of amplimer products
were carried out accordingly to methods already detailed
[21]. Actin was used as the control gene to normalize
individual gene expression.
Data analysis
Statistical analysis of the data and expression of the values
of differential transcription were performed as previously
described [21].
The overall survival (OS) and cumulative probability
analyses were performed using the Kaplan–Meier
method and the survival curves were compared by the
log Rank test, using IBM® SPSS® Statistics V.21.
Tissue microarray construction and
immunohistochemistry
Representative tumor regions were identified in each
sample and selected to make a tissue microarray con-
taining three tissue cores from each sample of LSCRC.
After 5 min at 60 °C the tissue microarray blocks were
cut in 4 μm thick sections, ready for immunohistochem-
ical techniques. Tissue sections were treated, prepared
and immunostained as previously described [21]. For the
detection of chondroitin 6-sulfotransferase-2, syndecan
1, CD117, NDST1 and glypican-4, sections were heated
in high pH Envision FLEX target retrieval solution at
65 °C for 20 min and then incubated for 20 min at room
temperature in the same solution. To detect perlecan,
CS, HS2ST1, UST, CS, CS4ST, the same procedure was
followed except that the final step was omitted and the
sections were instead incubated overnight at 4 °C in a
humid chamber with primary antibodies. The antibodies
and the dilution are detailed in the Additional file 1.
After the first incubation, sections were rinsed in the same
buffer, and incubated with the following secondary anti-
bodies; anti-rabbit, anti-mouse EnVision system-labelled
polymer (DakoCytomation) and anti-goat diluted 1:100
(Santa Cruz Biotechnology) for 1 h at room temperature.
Finally, the sections were washed and the immunoreaction
visualized using 3–3’DAB as a chromogen. The sections
were studied and photographed under a light microscope
(Eclipse 80i; Nikon Corporation, Tokyo, Japan).
Results
Analysis of differential gene expression
Almost all the genes known to be involved in the various
steps defined in the biosynthesis of HSPGs in LSCRCs
were investigated in this work. The tumor samples used in
the present study, all of them non-mucinous, were ob-
tained from the Tumor Bank of IUOPA. Diagnosis was
made by staining with hematoxylin and eosin according to
the criteria of the World Health Organization (WHO).
Applying the TNM classification, all tumors were at the
T3 stage (muscularis propria affected) and were classified
into two groups depending on the presence (at least N1) or
absence (N0) of lymph node metastases, which resulted in
10 samples being included in the first group and 8 in the
second. Non-metastatic tumor samples, all of them of stage
IIA, came from 7 male patients and 3 female patients, all of
them between the ages of 60 and 81 years. Among the
metastatic samples, i.e. stage IV, 5 were from male patients
and 3 from females, and ages ranged from 60 to 88 years.
We used qRT-PCR to perform a quantitative analysis of
mRNA expression. In many of the genes where we were able
to detect differences between normal tissues and tumors, we
complemented the studies using immunohistochemistry.
Differential expression of genes encoding core proteins
carrying HS chains
Only 13 genes encode HSPGs core proteins. The great
majority of cell surface HSPGs are related to two gene
families, the syndecans and the glypicans, which comprise
4 and 6 isoforms, respectively (SDC1–4 and GPC1–6); the
three remaining molecules are arranged in the extracellu-
lar matrix and are perlecan (PRCAN), agrin (AGRN) and
collagen type XVIII (COL18A1) [22]. Within the group of
syndecans, no significant differences in transcript levels of
isoforms 2, 3 and 4 were detected, irrespective of the pres-
ence or absence of lymph node metastasis (Fig. 1a and b).
However, 80% of non-metastatic tumors (p < 0.05) exhib-
ited an overexpression of syndecan 1 mRNA, the average
being a more than 3-fold increase, as did 87% of meta-
static tumors (p < 0.05), although in this case the mean in-
crease was around 70% (Fig. 1c).
Immunohistochemistry was used to investigate changes in
syndecan 1, using monoclonal anti-SDC1 (Fig. 2a-d).
Non-metastatic tumors demonstrated considerable reactivity
but, interestingly, lower than those detectable in healthy tis-
sue (Fig. 2a); In addition, there were differences in the
localization of the immunostaining: in the healthy tissue it
appeared to be associated with the cellular membranes, while
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in the tumor tissue it was also detected in the extracellular
matrix, probably due to shedding of cell membrane-bound
proteoglycans (Fig. 2b). In contrast, and surprisingly, the
metastatic tumors showed a dramatic decrease in staining,
indeed largely non-existant, while labeling was very clear in
the adjacent normal mucosa (Fig. 2c and d).
Analysis of the expression of the different glypicans re-
vealed the presence of transcripts for the 6 different isoforms,
although their levels varied widely depending on the particu-
lar isoform examined. The qRT-PCR results were unable to
detect significant changes in the levels of transcripts in
non-metastatic tumors (Fig. 1a), while in metastatic LSCRCs
GPC4 was overexpressed in 87% of cases (p < 0.05), with an
approximately 3-fold increase (Fig. 1b and c). These results
were also observed by immunohistochemistry, where GPC4
staining was found to be elevated in tumor tissue (Fig. 2e
and f). In metastatic tumors, a significant downregulation of
GPC6 was also detected, its levels being reduced in 87% of
the cases analyzed (p < 0.05), with values being around 26%
of those determined in healthy tissues (Fig. 1b and c).
Two other part time HSPGs may be present in the cell
membrane in addition to syndecans and glypicans: beta-
glycan (TGFBR3) and CD44v3 [22]. The results from the
qRT-PCR analysis identified transcripts of these genes in
both metastatic and non-metastatic tumors as well as in
normal tissue (Fig. 1a and b), although there were no
significant differences in their transcript levels (Fig. 1c).
qRT-PCR analysis of serglycin, a cell-associated PG which
is intracellular [23], unlike other HSPGs, showed decreased
levels, around 35% of the values obtained for healthy tis-
sues, independent of the metastatic nature of the tumor
(Fig. 1), and affecting 70–75% of the samples analyzed (p <
0.05). Since serglycin is principally located in mast cell
secretory granules [23], we were prompted to attempt to
detect these cells through immunohistochemical studies
using the antibody CD117. The results highlighted a dra-
matic reduction in the population of mast cells in tumoral
compared to non-tumoral colon mucosa (Fig. 2g and h).
As regards extracellular matrix PGs, no significant dif-
ferences in levels of agrin were found (Fig. 1a and b), al-
though transcription levels of perlecan decreased in
about 75% of tumor samples (p < 0.05), with values being
around 60% lower than those obtained for healthy tis-
sues (Fig. 1c). These results were also observed by im-
munohistochemistry, where perlecan displayed faint
staining in normal tissues, while in metastatic and
non-metastatic LSCRCs staining in the tumor stroma
was weaker still (Fig. 3a and b). Moreover, a significant
underexpression of collagen XVIII in non-metastatic tu-
mors was detected (Fig. 1a and b), which was 70% lower
a
b
c
Fig. 1 Differential transcription of genes encoding HSPGs. a, b, Relative transcript abundance of mRNAs for healthy tissues (gray bars) and tumors
(black bars). Genes that show significant differences in their transcription levels are highlighted. a, Non-metastatic LSCRCs. 1: syndecan-1 (p < 0.05); 4:
perlecan (p < 0.05); 5: collagen XVIII (p < 0.05); serglycin (p < 0.05). b, Metastatic LSCRCs. 1: syndecan-1 (p < 0.035); 2: glypican-4 (p < 0.05); 3: glypican-6
(p < 0.05); 4: perlecan (p < 0.05); 8: serglycin (p < 0.05). c, Relative expression ratio of genes that show statistically significant differences in expression in
non-metastatic (●) or metastatic (■) CRCs. Values on the Y axis are on a logarithmic scale and the spreads represent the standard deviations
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Fig. 2 Immunolocalization of cell HSPGs. a-d, Histological localization of syndecan-1 expression. a, Normal mucosa showing intense staining associated
with the cell membrane. Plasma cells in lamina propria are also stained positively. b, Non-metastatic tumor displaying decreased immunoreactivity and
weak staining in ECM (arrows). Plasma cells in lamina propria are also positively stained; magnification 40X. c, Metastatic tumor and (d), Transition area
between normal colon mucosa and tumor; arrows indicate the loss of staining in the tumor region; magnification 20X and 10X respectively. e-f
Immunolocalization of glypican-4 expression in normal mucosa (e) and metastatic tumor (f); In the healthy tissue weak immunomarking is observed in
crypts and matrix which is stronger in the tumor tissue, as it also is in the fibrous tissue (arrow); magnification 40X. (g-h), Immunolocalization of mast cells
using CD117 antibody. Localization of mast cells in normal colon mucosa (g) and tumor (h). Arrows indicate the staining of mast cells in the normal
mucosa. The asterisks show the tumor area, where there is no detectable staining. Magnification 40X
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than that of healthy tissue (p < 0.05) (Fig. 1c), and ob-
served in 70% of the LSCRCs analyzed. In the case of
metastatic tumors, the differences observed approached
significance (p = 0.07), and transcription values were
around 50% lower in 70% of samples (Fig. 1c). However,
the expression of the protein could not be detected via
immunohistochemistry in either healthy tissue or tumor
samples (Fig. 3c and d).
Differential expression of genes encoding
glycosyltransferases involved in common linkage region
sequence and GAG chain synthesis
The synthesis of HS and CS chains is dependent on the
cooperation of a number of biosynthetic enzymes in the
Golgi. The initial step involves a tetrasaccharide glycan
linker being synthesized on a cognate serine residue of the
proteoglycan core, whose sequence is integrated by
xylose-galactose-galactose-GlcA [24, 25]. The genes encod-
ing the glycosyltransferases (GTs) involved in this process
are: XYLT1 and XYLT2, which ensures the initial transfer of
xylose residue; B4GALT7 and B3GALT6, responsible for
the sequential addition of the two residues of galactose; and
B3GAT1, B3GAT2 and B3GAT3, each of which encodes the
enzymes responsible for the transference of GlcA [26].
Transcripts for all these genes except B3GAT2 were de-
tected both in healthy tissues and in LSCRCs, but none of
them showed significant differences in their expression
levels (Fig. 4a and b).
The subsequent chain extension of HS involves the
transfer of a GlcNAc residue, followed by the sequential
addition of alternate GlcA and GlcNAc residues, which
results in a non-branched polymer. The mRNA levels of
none of the GTs involved in the synthesis of the HS chains
appeared modified in CRCs, including the enzymes in-
volved in the transference of the first glucosamine residue
(EXTL2, EXTL3) and those responsible for the subsequent
polymerization (EXT1, EXT2) (Fig. 4a and b).
The linker is shared by HS and CS chains, and the
addition of an N-acetyl-D-galactosamine (GalNAc) rather
than GlcNAc directs the pathway towards the biosynthesis
of CS. In this case, chain extension takes place through the
sequential addition of alternate GlcA and GalNAc residues
[23, 27]. One of the genes involved in the transference of the
first GalNAc residue, CSGALNACT2 appeared downregu-
lated by around 50% in 70% of non-metastatic LSCRCs (p <
0.05), whereas in metastatic tumors the differences were not
statistically significant (p= 0.32). No differences in the tran-
scription of the chondroitin synthases CHSY1 and CHSY3
were detected, however, the chondroitin polymerizing factor
CHPF was overexpressed in all the tumoral samples ana-
lyzed, both metastatic and non-metastatic (p < 0.05) (Fig. 4c).
Differential expression of genes involved in HS chain
modification
As the HS chain polymerizes, a series of modifications occur,
the first being the removal of acetyl groups from GlcNAc
residues. This is followed by the sulfation of the amino
group, which is catalyzed by four different isoforms of
N-deacetylase/N-sulfotransferases: NDST1, NDST2, NDST3
and NDST4 [12, 13]. Transcripts were found for only two of
Fig. 3 Immunolocalization of ECM HSPGs. a-b Immunolocalization of perlecan expression. a, Normal mucosa showing positive staining in the cell
cytoplasm and in the basement membranes, magnification 40X. b, Non-metastatic tumors; magnification 40X. c-d, Immunolocalization of
collagen XVIII expression. c, Normal mucosa and (d), Non-metastatic LSCRCs showing no positive immunoreactivity; Magnification 40X
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these isoforms, NDST1 and − 2, but these were quantified in
all healthy and tumoral tissues. NDST3 transcripts, on the
other hand, were detected in only a percentage of tumors
(less than 40%), while NDST4 was undetectable in most
samples (Fig. 5a and b). NDST2 appeared downregulated by
65% in non-metastatic LSCRCs (p < 0.05) and by 75% in
metastatic (p < 0.01), in 80 and 100% of the respective
samples (Fig. 5c). In metastatic tumors, NDST1 transcription
levels were around 60% lower than controls in 75% of cases
(p < 0.05) (Fig. 5), while in non-metastatic samples, the de-
crease was only around 40%, in 60% of the cases, though it
was not statistically significant (p= 0.07) (Fig. 5). Changes in
NDST1 were also analyzed by immunohistochemistry, show-
ing weak staining in healthy tissues, mainly in crypts and in
the extracellular matrix, which was even weaker in tumoral
tissue (Fig. 6a and b).
The next modifications of the HS chain include two
reactions involving the GlcA residue: epimerization into
IdoA, catalyzed by the enzyme C5-GlcA epimerase
(encoded by GLCE), and the addition of sulfate groups
at C2, catalyzed by the enzyme HS 2-O-sulfotransferase
(HS2ST1). In non-metastatic LSCRCs the two genes ex-
perienced an upregulation of about 2.5 and 2 fold re-
spectively (p < 0.05 in each case) (Fig. 5), affecting 80%
of samples. Moreover, there was a strong positive correl-
ation between the levels of upregulation of the two genes
for each individual sample (r Spearman 0.78). Changes
in HS 2-O-sulfotransferase were also analyzed by immu-
nohistochemistry, where a positive immunoreactivity
was observed for certain basal cells, as well as weak
staining in Lieberkhün crypts, with a vesicular dotted
pattern; the labelling was slightly increased in tumoral
tissues (Fig. 6c and d).
With regard to the genes responsible for the sulfation
in C6 of glucosamine, in the healthy tissue the existence
of transcripts of the three isoforms was demonstrated.
In contrast, isoform 3 was not detected in any of the
tumor samples, and isoform 1 only appeared in 80% of
the metastatic tumors, where it was downregulated
around 70% (p < 0.05) (Fig. 5).
The addition of a sulfate group at C3 of glucosamine
is the final step in the biosynthesis of HS chains in the
Golgi, catalyzed by HS 3-O-sulfotransferase isoforms 1–
6 (HS3ST1, HS3ST2, HS3ST3A1, HS3ST3B1, HS3ST4,
HS3ST5 and HS3ST6) [10, 11]. No transcripts were de-
tected for some of the genes and, for those that were,
levels varied considerably depending on each specific
isoform. Only HS3ST6 showed statistically significant
a
c
b
Fig. 4 Transcription of genes encoding the glycosyltransferases involved in the biosynthesis of HS and CS chains. a, b, Relative transcript
abundance of mRNAs for healthy tissues (gray bars) and tumors (black bars). Genes that display significant differences in their transcription levels
are highlighted. a, Non-metastatic LSCRCs. 1: N-acetylgalactosaminyltransferase 2 (p < 0.05); 2: chondroitin polymerizing factor (p < 0.05). b,
Metastatic LSCRCs. 2: chondroitin polymerizing factor (p < 0.05). c, Relative expression ratio of genes that showed statistically significant
differences in expression in non-metastatic (●) and metastatic (■) LSCRCs. Values on the Y axis are on a logarithmic scale and the spreads
represent the standard deviations
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c
Fig. 5 Differential transcription of genes involved in the modification of HS chains. a, b, Relative transcript abundance of mRNAs for healthy
tissues (gray bars) and tumors (black bars). Genes that display significant differences in their transcription levels are highlighted. a, Non-metastatic
LSCRCs. 2: N-deacetylase/N-sulfotransferase 2 (p < 0.05); 3: C5-GlcA epimerase (p < 0.05); 4: 2-O-sulfotransferase (p < 0.05); 6: 6-O-sulfotransferase 3
(p < 0.001); 7: 3-O-sulfotransferase 6 (p < 0.05). b, Metastatic LSCRCs. 1: N-deacetylase/N-sulfotransferase 1 (p < 0.05); 2: N-deacetylase/N-
sulfotransferase 2 (p < 0.01); 5: 6-O-sulfotransferase 1 (p < 0.05); 6: 6-O-sulfotransferase 3 (p < 0.001); 7: 3-O-sulfotransferase 6 (p < 0.001). c, Relative
expression ratio of genes that show statistically significant differences in expression in non-metastatic (●) and metastatic (■) LSCRCs. Values on
the Y axis are on a logarithmic scale and the spreads represent the standard deviations
Fig. 6 Immunolocalization of enzymes involved in the modification of HS chains. a-b Immunolocalization of N-deacetylase/N-sulfotransferase-1. a,
Normal mucosa showing positive weak staining mainly in crypts (arrow) and in the extracellular matrix (asterisk). b, Metastatic tumor showing a
decrease in staining in both locations; magnification 40X. c-d, Immunolocalization of HS 2-O-sulfotransferase. c, Normal mucosa showing faint
staining in the crypts, with a vesicular punctate pattern (arrow), and in some basal cells, no marking in the matrix (d), Non-metastatic LSCRCs with
a slightly higher immunoreaction; magnification 40X
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differences, with levels being 97% lower on average in
non-metastatic tumors than controls (p < 0.05), although
there was great variability between samples, and it was
undetectable in metastatic tumors (p < 0.001) (Fig. 5).
Finally, HS patterning modifications occur at the cell sur-
face, carried out by two cell surface sulfatases, SULF1 and
SULF2, which remove glucosamine-6S groups from specific
regions [10, 11]. None of these genes displayed any alter-
ations in their transcription levels in LSCRCs (Fig. 5).
However, since the results did demonstrate changes in
the transcription levels of several enzymes involved in the
modification of HS chains, we deduced that the structure
of HS chains could also be altered. Consequently, we ana-
lyzed the distribution of HS molecules by immunohisto-
chemistry using the specific antibody 10E4 which is able
to recognize N-sulfated epitopes. Normal mucosa dis-
played positive cytoplasmic and nuclear staining in both
absorptive and goblet cells, while in tumors, changes in
the distribution and intensity of the immunostaining was
detected (Fig. 7). LSCRCs showed variable degrees of sul-
fated HS chains, with a predominance of nuclear staining,
which varied in its degrees of intensity (Fig. 7).
Differential expression of genes involved in CS chain
modification
Up to four different reactions can be involved in the
modification of CS chains: GalNAc residues can be
sulfated at C4 or C6, and IdoA residues can be epimer-
ized at C5 or sulfated at C2 [24, 26]. Sulfation at C4 of
GalNAc residues is catalyzed by four different enzymes,
encoded by the genes CHST11–14, and the transcription
of two of these genes appeared downregulated in
LSCRCs. CHST11 levels dropped by more than 60% in
non-metastatic (p < 0.05) and around 85% in metastatic
tumors (p < 0.01), affecting 85 and 100% of samples re-
spectively (Fig. 8). CHST12 was also downregulated in
both types of tumor, with transcription levels decreasing
about 60% in non-metastatic and 70% metastatic
LSCRCs (p < 0.05), in 80 and 90% of the respective sam-
ples (Fig. 8). No statistically significant alterations were
detected for the isoforms encoded by CHST13 and
CHST14. CHST12 protein expression was also analyzed
by immunohistochemistry, showing healthy tissue im-
munoreaction in crypts and ECM, while staining was
weaker in tumoral tissue (Fig. 9a and b).
Sulfation at C6 of GalNAc is catalyzed by three distinct
enzymes, encoded by the genes CHST15, CHST3 and
CHST7 [24, 26]. No transcripts for CHST15 were detected
in any of the samples studied; CHST3 was downregulated
about 80% in non-metastatic tumors (p < 0.05) in 80% of
the samples analyzed, while CHST7 decreased an average
of more than 85% (p < 0.01) in all the metastatic samples
(Fig. 8). Changes in CHST3 were also evaluated immuno-
histochemically but, interestingly, in this case the results
Fig. 7 Immunolocalization of sulfated domains of HS chains using
anti-HS 10E4 in colon mucosa and adenocarcinomas. a, Normal
mucosa showing varying positive cytoplasmic (mostly perinuclear)
and nuclear staining in both absorptive and goblet cells. (b, c),
Colon adenocarcinomas showing variable degrees of highly sulfated
domains of HS chains. A predominance of nuclear staining was
noted, varying in degree of intensity from moderate (b) to negative
or focally weak nuclear staining (c). Magnification 40X
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showed an overexpression of the protein, with healthy tis-
sue remaining unstained while tumoral tissue showed in-
tense immunoreactivity in crypts (Fig. 9c and d).
Transcription levels of the two enzymes involved in
the modification reactions of uronic acid residues were
also significantly altered. DSE decreased by between
around 50 and 80% in non-metastatic patients (p < 0.05),
the differences in metastatic tumors were not, however,
significant (Fig. 8). There was also a 10 fold decrease in
UST in tumors, with all non-metastatic samples being
affected, and 80% of metastatic (Fig. 8). The decrease
was also determined at the protein level by immunohis-
tochemistry, which revealed decreased staining in tumor
samples (Fig. 9e and f).
The existence of alterations in the expression of genes
involved in both the polymerization and the modification
of the CS chains prompted us to conduct an immunohisto-
chemical analysis of the structure of these saccharide chains
using the specific antibody CS-56. Healthy tissues displayed
most staining in the stroma, while staining intensity in-
creased in tumors, where it was associated with the fibrous
elements of the matrix in non-metastatic LSCRCs, as well
as the cytoplasm of some cells (Fig. 10).
Relationship between alteration in gene expression and
survival data
Of the genes that showed statistical differences in their
expression patterns, we found better survival medians in
those patients with overexpression of GPC4 and HS6ST3,
and underexpression of GPC6, PRCAN, NDST1, HS6ST1,
CHST11, CHST3, DSE and UST, although statistically better
OS was only related to the underexpression of GPC6 (68.10
vs. 37.33 months, p = 0.077), NDST1 (68.10 vs.
50.00 months, p = 0.035), HS6ST1 (79.47 vs. 51.40 months,
p = 0.068) and CHST12 (68.10 vs. 12.30 months, p = 0.026)
(Additional file 2: Table S2, and Additional file 3: Figure
S3). This behavior persisted irrespective of lymph node in-
volvement, especially when there was underexpression of
NDST1 (pN0 57.67 vs 12.30, pN1 68.10 vs. 50.00 months,
p = 0.047) and CHST12 (pN0 57.67 vs. 9.13 months, pN1
68.10 vs. 37.33 months, p = 0.042), and there was also a
trend for the downregulation of GPC6 (N0 57.67 vs.
9.13 months, pN1 68.10 vs. 37.33 months, p = 0.076) and
HS6ST1 (pN0 57.67 vs. 9.13 months, pN1 68.10 vs.
37.33 months, p = 0.042). On the other hand, overexpres-
sion of SDC1, CHPF, and HS2ST1, and downregulation of
COL18A1, SRGN and CSGALNACT2 were linked to poorer
a
b
c
Fig. 8 Differential transcription of genes involved in the modification of CS chains. a, b, Relative transcript abundance of mRNAs for healthy tissue
(gray bars) and tumors (black bars. Genes that display significant differences in their transcription levels are highlighted. a, Non-metastatic LSCRCs. 1:
chondroitin 4 sulfotransferase 1 (p < 0.05); 2: chondroitin 4 sulfotransferase 2 (p < 0.05); 3: chondroitin 6 sulfotransferase 1 (p < 0.05); 5: dermatan sulfate
epimerase (p < 0.05); 6: uronyl-2-sulfotransferase (p < 0.01). b, Metastatic LSCRCs. 1: chondroitin 4 sulfotransferase 1 (p < 0.05); 2: chondroitin 4
sulfotransferase 2 (p < 0.05); 4: chondroitin 6 sulfotransferase 2 (p < 0.01); 6: uronyl-2-sulfotransferase (p = 0.012). c, Relative expression ratio of genes
that show statistically significant differences in expression in non-metastatic (●) and metastatic (■) LSCRCs. Values on the Y axis are on a logarithmic
scale and the spreads represent the standard deviations
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outcomes, though the effect was not statistically significant.
No differences in OS were found for the expression of
NDST2, GLCE, HS3ST6, and CHST7.
Discussion
The abnormal expression of HSPGs in cancer and stromal
cells can serve as a biomarker for tumor progression and
patient survival [25]. HS fine structure is determined by
the cell-type specific expression of only certain isoforms
of some of the biosynthetic enzymes, notwithstanding the
existence in some specific cases of regulation at the level
of translation or enzymatic catalysis [28–30]. In a previous
work, we have described the alterations that take place in
RSCRCs which affect both the core proteins of HSPGs
and the different enzymes responsible for the synthesis of
the GAG chains, as well as the differences in these
changes depending on the presence or not of metastasis
in malignances [21]. In the present study, we provide a
similar analysis focused on LSCRCs in order to determine
whether there are any differences between left- and right
sided pathologies. As in the previous study, here we have
considered the comparative analysis of tumors at the T3
stage, where the muscularis propria is affected, and classi-
fied the tumors depending on the presence or absence of
lymph node metastasis.
Two gene families, syndecans and glypicans, account for
most cell surface HSPGs in humans, along with a few
part-time proteins [22]. Transcripts for all syndecan species
were detected in LSCRCs, but only syndecan-1 mRNA ap-
peared overexpressed in most tumors, independent of the
presence of metastasis. Although some previous studies
using colon carcinoma cells have described alterations in the
transcriptions of syndecan-2 and -4 [16], our previous work
on RSCRCs was only able to detect overexpression of
syndecan-1 in metastatic tumors [21]. Interestingly, in this
work the analysis of the expression of syndecan-1 protein
using immunohistochemistry provided the noteworthy
finding that non-metastatic LSCRCs displayed lower
Fig. 9 Immunolocalization of enzymes involved in the modification of CS chains. a-b Immunolocalization of chondroitin 4 sulfotransferase 2. a,
Normal mucosa showing positive staining in crypts (arrow). b, Metastatic tumor showing a decrease in staining; magnification 40X. c-d,
Immunolocalization of chondroitin 6 sulfotransferase 1. c, Normal mucosa, magnification 40X. d, Transition area between normal colon mucosa
and tumor; the healthy tissue appears unmarked (asterisks), while the tumor shows intense immunoreactivity in the crypts (arrow), magnification
40X. e-f, Immunolocalization of uronyl-2-sulfotransferase. e, normal mucosa, (f), tumor, magnification 40X
Crespo et al. BMC Cancer  (2018) 18:687 Page 11 of 17
immunoreactivity to that detected in normal tissues from
the same patients, while the metastatic tumors showed a
dramatic decrease in staining. Furthermore, non-metastatic
tumors have a certain level of staining in the extracellular
matrix, suggesting the shedding of cell membrane-bound
proteoglycans. These results are very similar to those
previously described in RSCRCs, where we suggested that
the expression of syndecan-1 involves additional
post-transcriptional mechanisms, such as protein translation,
degradation, inhibition by feedback loops or miRNA regula-
tion [21]. There is evidence for the post-transcriptional
regulation of syndecan-1 expression in, for example, pancre-
atic cancer and peritoneal macrophages [30, 31]. Our data
also correlate well with other previous immunohistochemical
studies which have described a loss of expression of
syndecan-1 in CRCs, some of which have been found to cor-
relate with tumor stage and metastasis [32–35]. Upregulation
of syndecan-1 has been described in some types of tumors,
and it has been postulated that this aberrant expression may
play a key role in promoting growth factor signaling in can-
cer cells [36]. In contrast, other malignances have been
found to show downregulation of this molecule, indicating
that this HSPG could well serve as a prognostic marker in a
cancer-type-specific manner [36].
The glypican family comprises six cell surface HSPGs
that are involved in the regulation of several signaling path-
ways, where, depending on biological context, they either
stimulate or inhibit activity [37]. As such, tumor progres-
sion is affected by their activity, with abnormal expression
being linked to various human tumors [25]. In the samples
analyzed in this study, their relative expression patterns
were quite similar to those observed in RSCRCs [21].
However, very few transcriptional changes were detected: in
isoforms 4 and 6 in metastatic tumors, where, moreover,
these alterations were markedly different from those ob-
served in ascending tumors, where there is a great underex-
pression of glypican 1 in all types of tumors; and in
isoforms − 3 and − 6 in non-metastatic tumors [21]. Unlike
the other isoforms, relatively little is known concerning the
expression or functional roles of glypican-4 and -6 in tu-
mors. However, the ability of glypican-4 to uncouple pluri-
potent stem cell differentiation from tumorigenic potential
has been recorded [38], while the reduced expression or
loss of function of glypican-6 has been described in retino-
blastoma and autosomal-recessive omodysplasia [39, 40].
Betaglycan and CD44v3 are part time membrane
HSPGs, meaning that they occur either with or without
HS chains [22]. Although the expression of CD44v3 in
CRCs has been described as being related to more ad-
vanced pathological stage and poorer prognosis [41], in
this study no statistically significant differences in any
type of LSCRCs were found, mirroring our previous
findings for RSCRCs [21]. The other part time HSPG an-
alyzed was betaglycan, whose expression in tumor cells
Fig. 10 Immunolocalization of CS. a, Normal mucosa showing
preferential staining in the stroma. b, Non-metastatic tumor,
showing increased labelling, associated with the fibrous elements of
the matrix, and also appearing on the crests with spotted staining in
the cytoplasm (arrow). c, Metastatic tumor, in which the
immunostaining is greater in all regions, and can also be observed
in the cytoplasm of crypt cells (arrows). Magnification 40X
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appears to play an important role in the progression of
the pathology [42]. However, in relation to CRCs, al-
though this molecule appeared underexpressed in
non-metastatic RSCRCs [21], in this study no significant
differences between tumor and healthy tissues was de-
tected in LSCRCs.
Another cell-associated HSPG is serglycin, which consti-
tutes a separate category since it has the peculiarity of being
located intracellularly [23]. Transcript levels of this gene in
this work were significantly reduced, both in metastatic and
non-metastatic tumors, following a similar pattern to that
previously observed in RSCRCs [21]. Serglycin is mainly
found in hematopoietic and endothelial cells, and the prin-
cipal GAG chains found bound to this core protein are CS,
except in mast cells where CS type E or heparin may be
present, depending on the cell’s origin [23, 43]. Mast cells
in LSCRCs were drastically reduced in tumors compared to
non-tumor colon mucosa, which could be, at least in part,
the reason for the decrease in protein expression. A num-
ber of previous studies have described alterations in sergly-
cin in different tumors [44–46], and it is also worth noting
that results analogous to those described in this work, in-
volving both downregulation of transcription and reduction
in the population of mast cells, have also been obtained in
RSCRCs [21], suggesting that this is a common feature of
both CRC types.
Three HSPG species are located at the ECM: agrin,
perlecan and collagen XVIII, and the latter two showed
significant downregulation in tumoral samples, which is
interesting considering that these two species also ap-
peared modified in RSCRCs [21]. Perlecan expression,
both at the transcription and the protein level, was di-
minished in tumors, independent of the presence or ab-
sence of lymph node metastasis. Perlecan, a critical
regulator of growth factor-mediated signaling and angio-
genesis, is an essential element in maintaining basement
membrane homeostasis [47], likely indicating that it has
a role to play in the progression of CRCs.
Collagen XVIII appeared downregulated to a statistically
significant extent only in non-metastatic LSCRCs, while in
RSCRCs its expression was significantly reduced in both
metastatic and non-metastatic tumors [21]. However, de-
creases of about 50% were found in 70% of metastatic
LSCRCs, a result that approached significance (p = 0.07),
leading us to suggest that the results observed could be
dependent on the individual sample analyzed, and that the
real effect might occur similarly in all CRCs, regardless of
their location. Several reports in other malignances
describe different types of alterations in collagen XVIII
depending on type of tumor, e.g., its expression increases
in ovarian and pancreatic cancer, while it diminishes in
liver and oral cancer [25].
In summary the patterns of alterations in the levels of
expression of HSPG core proteins in CRCs is quite similar
for ECM molecules, syndecans and serglycin, independent
of tumor location, while glypicans display differences
between RS- and LS- malignances.
The tissue-specific expression of individual HSPGs will
determine when and where HS chains are expressed. For
GAG chain generation, it is necessary to regulate the
activity of many different enzymes, mainly GTs, located in
the lumen of the Golgi apparatus [10]. The initial step in
the biosynthesis of the chains is the creation of a tetrasac-
charide linkage region, followed by polymerization through
the consecutive addition of alternating GlcA and GlcNAc.
A number of works have described variations in HS levels,
both increases and decreases, in different tumor types [15,
48], including for CRCs, where decreases have been re-
ported [17, 49]. However, in this work, it was not possible
to determine the existence of significant differences in the
transcription levels of any of these genes in LSCRCs. This
finding contrasts with the results previously described for
metastatic RSCRCs, in which B3GAT1 expression de-
creased, particularly in non-metastatic RSCRCs, where sev-
eral genes responsible for the synthesis of the linker
(XYLT1, XYLT2, B3GAT1) and the polymerization of the
chain (EXT1) were downregulated [21].
During HS biosynthesis, various sulfation and epimeriza-
tion reactions take place which are responsible for the fine
structure of the saccharide chain. The first reaction in-
volved in polymer modification is the removal of acetyl
groups from GlcNAc residues, after which the amino group
is sulfated, catalyzed by four different isoforms of
N-deacetylase/N-sulfotransferases [10]. The tissue distribu-
tion of NDST1 and NDST2 broadly overlap [50], and tran-
scripts for both were detected in all samples analyzed in
this study, with NDST2 appearing downregulated in all
LSCRCs, while NDST1 transcription was downregulated in
all metastatic tumors and in 60% of non-metastatic. In con-
trast, previous work with RSCRCs has shown that both iso-
forms were underexpressed, but only in the non-metastatic
patients [21]. NDST4 was undetectable in most samples in
the current work, while NDST3 transcripts were detected
in only a small percentage of tumors. Expression of NDST3
and NDST4 is principally restricted to the period of embry-
onic development [51]. That said, in certain tumor types,
expression of these molecules has been described, for ex-
ample, NDST4 in breast cancer [51], although in RSCRCs
neither was detected [21].
The next steps in the synthesis of the HS chains include
the epimerization of GlcA into IdoA, an action catalyzed
by the enzyme C5-GlcA epimerase, along with O-sulfation
at C2 of uronic acid [11, 12]. An overexpression in the
transcription levels of the two genes involved, GLCE and
HS2ST1, was detected in non-metastatic LSCRCs in this
study, although not in metastatic tumors, in contrast to
our previous study in RSCRCs which found no alterations
in the expression of these genes [21].
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The addition of an O-sulfate group at C6 is mediated by
enzymes encoded by the genes HS6ST1–3, each of which
is specific to a particular substrate and differs in its tissue
expression [52]. Transcripts for the three isoforms were
identified in the healthy tissue studied here, but HS6ST3
mRNAs were not detected in tumor samples, neither
metastatic nor non-metastatic. Meanwhile, HS6ST1
appeared downregulated in metastatic LSCRCs. These
results show a pattern different from that previously
described in RSCRCs, where HS6ST2 was not detected in
either tumor type or in healthy tissue, and HS6ST1
appeared deregulated in non-metastatic tumors [21].
The last, and largest, family of enzymes involved in the
biosynthesis of HS is the 3-O-sulfotransferases, which com-
prises seven different members (HS3ST1–6). In LSCRCs,
only isoform − 6 expression appeared altered, its expression
being diminished in non-metastatic tumors, although it
was not detectable in metastatic forms. Again the data
differ from those obtained in RSCRCs, where none of the
isoforms appeared modified in metastatic tumors, and
HS3STB1 and HS3ST5 were underexpressed only in
non-metastatic ones [21]. 3-O-sulfation is a relatively rare
modification, and it has only been found to influence a
small number of proteins thus far [53]. That said, several
studies have reported 3-O-sulfation alterations in different
tumors [15, 48], and it has been suggested that certain pat-
terns of 3-O-sulfation may be responsible for the appear-
ance of cancerous phenotypics [25].
Once the HS biosynthetic process has been completed, 6S
groups present at the glucosamine residues can be
post-synthetically edited from the chain, suggesting that it
may have special regulatory importance. The reaction is car-
ried out by two endosulfatases located on the cell surface,
SULF1 and SULF2 [27], and alterations in the expression of
these genes in various tumor types, either up- or downregu-
lation, have been reported [15, 48]. In the case of LSCRCs,
transcript levels of none of these genes were found to be al-
tered, mirroring the results previously observed in RSCRCs,
where there were also no alterations [21].
Analysis of the HS structure by immunohistochemistry
showed differences between normal mucosa and tumors
as regards the intensity and distribution of the mole-
cules. It is possible that these differences are caused by
structural changes brought about by alterations in the
transcription levels of HS biosynthetic enzymes.
Some of the HSPGs analyzed in this study are hybrid
molecules, with both HS and CS side chains [54], mak-
ing it interesting to extend the study to the genes in-
volved in the biosynthesis of this GAG. In addition,
changes in CSPGs associated with CRCs, such as versi-
can and decorin, have been found [55], as well as alter-
ations of the CS chains in RSCRCs [21].
CS chain extension takes place through the sequential
addition of alternative GlcA and GalNAc residues. Five
genes, CSGALNACT1, CSGALNACT2, CHSY1, CHPF and
CHSY3 encode the GTs involved in this process [56].
CSGALNACT2 transcription was downregulated in
non-metastatic LSCRCs, which coincides with what has
been described in RSCRCs, although in the latter the rest of
the genes involved, except CHPF, also experienced a de-
crease in their transcription levels [21]. Interestingly, CHPF
appeared overexpressed in all LSCRCs, as it was in meta-
static RSCRCs [21]. In other previous studies of CRCs, dif-
ferent changes have been described, although it must be
stressed that these studies involved colorectal cancers from
different locations and not only RSCRCs [57].
CS repeating disaccharide building units can be modi-
fied by epimerization of GlcA residues and by various
sulfations [57]. O-sulfation at C4 of GalNAc residues is
carried out by enzymes encoded by four genes
(CHST11–14), although in this work only CHST11 and
− 12 appeared underexpressed in all LSCRCs. This con-
curs with our previous study in RSCRCs that showed a
very similar expression pattern for these genes, although
in that case CHST14 was also underexpressed in all tu-
mors, irrespective of their metastatic features [21].
O-sulfation at C6 of GalNAc residues is performed by
three different genes, and CHST3 translation was down-
regulated in non-metastatic tumors, although immuno-
histochemistry showed the opposite result, i.e. that it
was upregulated. This apparent contradiction between
the two sets of results is similar to the case described
above for syndecan 1, and suggests the involvement of
additional post-transcriptional mechanisms [21]. Discor-
dances between mRNA and protein in complex bio-
logical samples have been widely analyzed and discussed
[58], and subsets of proteins displaying negative correl-
ation with mRNA expression values have been described
in some tumors [59]. In addition, CHST7 appeared
underexpressed in metastatic LSCRCs in this work. Al-
though very similar patterns of expression for the three
genes were previously found in RSCRCs, no alterations
in transcription were observed [21].
Both genes encoding the enzymes involved in the modifi-
cation reactions of uronic acid residues, DSE and UST, were
significantly altered, although DSE to a lesser extent, with
the difference not reaching significance in metastatic tu-
mors. The alterations observed once again followed a pat-
tern similar to that previously observed in the ascending
tumors, where both enzymes appeared downregulated [21].
The alterations in the CS chains as a result of the differ-
ences in expression of biosynthetic genes were analyzed by
immunohistochemistry using the specific antibody CS-56,
with clear differences found in the amount and location of
the staining, although it must be taken into account that
CS-56 antibody reacts preferentially with CS-D (sulfated at
C-2 and C-6), but is also able to recognize other types of
structures, including CS-A, -B, -C, and -E [60].
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In terms of survival, the small sample size and the
retrospective character of this study should be recog-
nized as a considerable limitation, but, despite this, sta-
tistically significant differences in the underexpression of
two genes were detected, along with a trend in two add-
itional genes, and this behavior seems to be maintained
regardless of lymph node involvement or not. Some of
the other genes found to be significantly dysregulated in
this work might also show a relationship with survival in
a bigger sample, therefore prospective studies with a lar-
ger study population are necessary.
Conclusions
In sum, analyzing the differential expression of the genes
involved in HSPG biosynthesis in LSCRCs has highlighted
that some of them showed significant changes in their tran-
script levels. When comparing the results with those previ-
ously described for ascending tumors, similarities can be
seen for different gene families, as well as notable differ-
ences that evidence the heterogeneous character of the two
pathologies. In contrast to RSCRCs, where non-metastatic
tumors showed more alterations than metastatic tumors, in
the case of LSCRCs the percentage was very similar, around
30%. With regard to HSPG core proteins, the patterns of
alterations in expression of ECM molecules, syndecans and
serglycin were quite similar, while glypicans displayed
differences between RS- and LS- malignances.
The synthesis of the HS chains did not show, in contrast
to RSCRCs, differences in the expression of the genes re-
sponsible for polymerization, but differences were evident
in those controlling sulfation and epimerization. Differ-
ences between LS- and RSCRCs were preferentially found
in the expression of genes involved in C6 and C3 sulfation
of glucosamine, but not in NDSTs or SULFs. Finally, the
synthesis of the CS chains showed differences with respect
to the RSCRCs which preferentially affected the
polymerization of the chains and the 6C sulfation of the
GalNAc residue. The differences described in this article
can help to understand some of the molecular differences
between the proximal and distal colorectum previously
described for various biomarkers.
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